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Abstract 
Mesoporous nanospheres in the system SiO2-CaO (NanoMBGs) with a hollow 
core surrounded by a radial arrangement of mesopores were characterized, labeled with 
FITC (FITC-NanoMBGs) and loaded with ipriflavone (NanoMBG-IPs) in order to 
evaluate their incorporation and their effects on both osteoblasts and osteoclasts 
simultaneously and maintaining the communication with each other in coculture. The 
influence of these nanospheres on macrophage polarization towards pro-inflammatory 
M1 or reparative M2 phenotypes was also evaluated in basal and stimulated conditions 
through the expression of CD80 (as M1 marker) and CD206 (as M2 marker) by flow 
cytometry and confocal microscopy. NanoMBGs did not induce the macrophage 
polarization towards the M1 pro-inflammatory phenotype, favoring the M2 reparative 
phenotype and increasing the macrophage response capability against stimuli as LPS 
and IL-4. NanoMBG-IPs induced a significant decrease of osteoclast proliferation and 
resorption activity after 7 days in coculture with osteoblasts, without affecting 
osteoblast proliferation and viability. Drug release test demonstrated that only a fraction 
of the payload is released by diffusion, whereas the rest of the drug remains within the 
hollow core after 7 days, thus ensuring the local long-term pharmacological treatment 
beyond the initial fast IP release. All these data ensure an appropriate immune response 
to these nanospheres and the potential application of NanoMBG-IPs as local drug 
delivery system in osteoporotic patients. 
 
Keywords: mesoporous bioactive glasses; nanospheres; osteoblasts; osteoclasts; 
ipriflavone. 
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1. Introduction 
Throughout life, bone tissue undergoes continuous remodeling that requires the 
concerted action of bone-forming osteoblasts and bone-resorbing osteoclasts [1]. 
Osteoblasts are mononuclear cells that differentiate from bone-specific mesenchymal 
stem cells and carry out three important roles: the synthesis and secretion of most 
proteins of the bone extracellular matrix (ECM), the induction of ECM mineralization 
and the regulation of osteoclast differentiation for bone resorption [2-4]. On the other 
hand, osteoclasts are multinucleated giant cells that differentiate from hematopoietic 
stem cells and perform the bone resorption by the attachment to the bone surface and 
the secretion of hydrogen ions and lysosomal enzymes that degrade the bone ECM 
producing irregular cavities [5-7].  Osteoblasts and osteoclasts can communicate with 
each other through mechanisms that involve direct cell-cell contact, ECM interactions 
and the release of different cytokines [8]. In this context, osteoblasts express M-Csf and 
Rankl genes, which are the two main genes required for osteoclast differentiation. 
Therefore, it is possible to obtain osteoclast-like cells in vitro by culturing osteoclast 
progenitor cells in the presence of the proteins encoded by these genes: the 
macrophage/monocyte-colony forming factor (M-CSF) and the receptor activator of 
nuclear factor kappa-B ligand (RANKL), respectively [9,10]. Osteoblasts also produce 
osteoprotegerin (OPG), a soluble receptor that acts as a decoy receptor for RANKL and 
negatively regulates osteoclast differentiation [11]. The continuous stimulation of 
mononuclear pre-osteoclasts with M-CSF and RANKL induces the osteoclastogenesis 
by promoting the fusion of these cells into multinucleated osteoclasts and the formation 
of "ruffled membrane", critical for bone resorption [12,13]. During resorption process, 
the attachment of osteoclasts to the bone surface involves the creation of the "sealing 
zone", rich in F-actin, which forms a ring to isolate the resorptive space (resorption 
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lacuna) from the surrounding bone [14,15]. Matrix-degrading enzymes (cathepsin K), 
hydrogen ions and chloride ions are released into the resorption lacunae by the ruffled 
membrane, formed by fusion of secretory vesicles into the plasma membrane within the 
sealing zone, producing acidification [16-18], the dissolution of the bone mineral 
component and the enzymatic degradation of the bone organic matrix [19,20]. The 
equilibrium between bone resorption by osteoclasts and bone formation by osteoblasts 
is necessary to maintain the structural skeleton integrity and mineral homeostasis [21]. 
The alterations of bone remodeling, that is influenced by mechanical, genetic, vascular, 
nutritional, hormonal and local factors, are involved in the pathogenesis of different 
skeletal diseases, including osteoporosis [22]. Antiresorptive and anabolic therapies, 
with different drugs and biomaterials, have been designed for the treatment of 
osteoporosis with the aim of activating bone formation or/and inhibiting osteoclast 
function and survival [23,24]. The in vitro evaluation of these potential treatments 
before their in vivo application, requires the design of experimental models, closer to 
physiological conditions, which allow osteoclasts and osteoblasts communicate with 
each other in the presence of drugs or/and biomaterials.  
In the present study, monocultures and cocultures of osteoblasts and osteoclast-
like cells were carried out to investigate in vitro the incorporation and the effects of 
mesoporous SiO2-CaO nanospheres (NanoMBGs) loaded with ipriflavone (IP). 
NanoMBG nanospheres are intended for osteoporosis treatment by intraosseous 
administration, so that they would be in direct contact with bone cells. Besides, binary 
SiO2-CaO compositions have widely demonstrated their bioactive behavior when tested 
with biological significant solutions [25]. IP is a synthetic isoflavone that inhibits bone 
resorption, maintains bone density and prevents osteoporosis [26]. Oral administration 
of 1,200 mg/day of IP in patients with primary hyperparathyroidism showed that 
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ipriflavone is also indicated in the treatment of metabolic bone diseases characterized by 
a high bone turnover [27]. IP is metabolized by first pass metabolism, which leads to the 
low bioavailability and variation in blood concentration. For this reason, the 
administration of IP loaded into nanoparticles for intracellular release is a very 
interesting alternative, since the amount of IP required to affect the bone cells funct ion 
would be much lower. 
 
2. Materials and methods 
2.1. Preparation and characterization of mesoporous SiO2-CaO nanospheres 
(NanoMBGs) and fluorescein isothiocyanate labeled nanospheres (FITC-NanoMBGs)   
The synthesis of hollow mesoporous SiO2-CaO nanospheres (NanoMBGs) was 
carried out by the method described by Li et al. [28]. 80 mg of poly(styrene)-block-
poly(acrylic acid) PS-b-PAA were dissolved in 16 ml of tetrahydrofurane (THF) at 
room temperature. This solution was subsequently poured in a hexadecyl trimethyl 
ammonium bromide (CTAB) solution, previously prepared by dissolving 160 mg of 
CTAB in 74 ml of deionized water and 2.4 ml of ammonia (28% w/v) and gently stirred 
in an incubator at 37ºC. The mixture was magnetically stirred for 20 minutes and a 
solution of 25 ml of TEP in 1.6 ml of ethanol was added drop by drop and stirred for 
another 20 minutes. Thereafter, a solution of 125 mg of Ca(NO3)·4H2O in 1.6 ml of 
water was also added and stirred for 10 minutes and, finally the silica source was 
incorporated as a solution of 0.52 ml of TEOS in 1.6 ml of ethanol. After stirring for 24 
hours, the product was collected by centrifugation at 10,000 rpm (g = 16.466) for 10 
minutes and washed three times with a mixture of ethanol-water (50:50). The product 
was dried at 30 ºC under vacuum conditions and the organic template was removed by 
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calcination at 550 ºC for 4 hours with a heating rate of 1 ºC min
-1
. All reactants were 
purchased from Sigma- Aldrich (St. Louis, MO, USA).  
For fluorescein isothiocyanate (FITC) labeling of NanoMBGs, 50 mg of 
nanospheres were degasified at 80ºC for 24 hours and resuspended in 4 ml of toluene. 
Besides, 44.3 l of aminopropyl triethoxysiliane (APTES) were dissolved in 0.5 ml of 
ethanol and reacted with 0.6 mg of fluorescein isothiocyanate for 5 hours. This solution 
was added dropwise on the NanoMBG suspension and reacted at 80ºC for 12 hours 
under nitrogen atmosphere. Finally, fluorescein labelled NanoMBGs (FITC-
NanoMBGs) were thoroughly washed and centrifuged several times at 10,000 rpm (g = 
16.466) for 10 minutes to remove the excess of fluorescein non-covalently adsorbed to 
the nanospheres. 
NanoMBGs were characterized by scanning electron microscopy (SEM) using a 
JEOL F-6335 microscope (JEOL Ltd., Tokyo, Japan), operating at 20 kV and equipped 
with an energy dispersive X-ray spectrometer (EDS). Previously, the samples were 
mounted on stubs and gold coated in vacuum using a sputter coater (Balzers SCD 004, 
Wiesbaden- Nordenstadt, Germany).  
Transmission electron microscopy (TEM) was carried out using a JEOL-1400 
microscope, operating at 300 kV (Cs 0.6mm, resolution 1.7 Å). Images were recorded 
using a CCD camera (model Keen view, SIS analyses size 1024 X 1024, pixel size 
23.5mm x 23.5mm) at 60000X magnification using a low-dose condition. 
Nitrogen adsorption/desorption isotherms were obtained with an ASAP 2020 
porosimeter. NanoMBGs were previously degassed under vacuum for 15 h, at 150 ºC. 
The surface area was determined using the Brunauer-Emmett-Teller (BET) method. The 
pore size distribution between 0.5 and 40 nm was determined from the adsorption 
branch of the isotherm by means of the Barret-Joyner-Halenda (BJH) method. The 
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surface area was calculated by the BET method and the pore size distribution was 
determined by the BJH method using the adsorption branch of the isotherm. 
Fourier-transform infrared spectroscopy was done using a Nicolet Magma IR 
550 spectrometer and using the attenuated total reflectance (ATR) sampling technique 
with a Golden Gate accessory.  
Thermogravimetric analysis (TGA) was carried out using a TG/DTA Seiko 
SSC/5200 thermobalance (Seiko Instruments, Chiva, Japan) between 50 ºC and 600 ºC 
at a heating rate of 1 ºC min
-1
, using aluminium crucibles and -Al2O3 as reference. 
 
2.2. Ipriflavone loading into NanoMBs (NanoMBG-IPs) 
Drug loading was carried out by dissolving 300 mg of IP (7-Isopropoxy-3-
phenyl-4H-1-benzopyran-4-one, Sigma-Aldrich, St. Louis, MO, USA) in 6 ml of 
acetone. Thereafter 80 mg of NanoMBGs were suspended in this mixture and stirred for 
24 hours to allow IP incorporation. Thereafter the NanoMBG-IP nanospheres were 
filtered under vacuum using a polyamide filter and thoroughly washed with water to 
remove the IP physiosorbed on nanosphere surface.  
2.3. Ipriflavone release from NanoMBG-IPs 
IP release test were carried out by placing 4 mg of NanoMBG-IPs in transwell 
inserts (0.4 μm pore size, Corning, USA) in 24 well culture plates. Due to the almost 
complete water insolubility of ipriflavone, a mixture of 2-propanol:water (60:40 v/v), 
already used in previous ipriflavone delivery assays [29-31] was chosen as release 
medium. Therefore, 1.5 ml of this mixture were added to the wells of the same plates in 
order to evaluate the drug release. UV–VIS spectrophotometry was employed for 
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measurements of the drug concentration (Unicam UV – 500 UV-Visible1100 
spectrophotometer) at 299 nm in quintuplicate. 
2.4. Culture of human Saos-2 osteoblasts 
Human Saos-2 osteoblasts (American Type Culture Collection, ATCC) were 
seeded in 6 well culture plates (Corning, USA), at a density of 10
5 
cells/ml, in 2 ml of 
Dulbecco's Modified Eagle Medium (DMEM) supplemented with 10% fetal bovine serum 
(FBS, Gibco, BRL), 1 mM L-glutamine (BioWhittaker Europe, Belgium), penicillin (200 
μg/ml, BioWhittaker Europe, Belgium), and streptomycin (200 μg/ml, BioWhittaker 
Europe, Belgium) at 37 ºC under a CO2 (5%) atmosphere. After 24 hours of culture in the 
presence or the absence of 50 μg/ml of NanoMBGs, the osteoblasts were washed with 
phosphate buffered saline (PBS), harvested using 0.25% trypsin-EDTA solution and 
counted with a Neubauer hemocytometer for the analysis of cell proliferation. Then, cells 
were centrifuged at 310 g for 10 min and resuspended in PBS for the analysis of cell cycle 
and apoptosis by flow cytometry as described below. 
2.5. Cell-cycle analysis and apoptosis detection by flow cytometry  
Cells were resuspended in PBS (0.5 ml) and incubated with 4.5 ml of ethanol 
70% during 4 hours at 4 ºC. Then, cells were centrifuged at 310 g for 10 min, washed 
with PBS and resuspended in 0.5 ml of PBS with 0.1 % Triton X-100, 20 µg/ml of 
propidium iodide (IP) and 0.2 mg/ml of RNAsa (Sigma-Aldrich, St. Louis, MO, USA). 
After incubation at 37 ºC for 30 min, the fluorescence of PI was excited by a 15 mW 
laser tuning to 488 nm and the emitted fluorescence was measured with a 585/42 band 
pass filter in a FACScan Becton Dickinson flow cytometer. The cell percentage in each 
cycle phase: G0/G1, S and G2/M was calculated with the CellQuest Program of Becton 
Dickinson and the SubG1 fraction was used as indicative of apoptosis. The conditions 
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for data acquisition and analysis were established using negative and positive controls 
with the CellQuest Program of Becton Dickinson. These conditions were maintained 
during all the experiments. At least 10,000 cells were analyzed in each sample. 
2.6. Culture of RAW-264.7 macrophages 
RAW-264.7 cells (American Type Culture Collection, ATCC) were seeded in 6 
well culture plates (Corning, USA), at a density of 10
5 
cells/ml, in 2 ml of Dulbecco's 
Modified Eagle Medium (DMEM) supplemented with 10% fetal bovine serum (FBS, 
Gibco, BRL), 1 mM L-glutamine (BioWhittaker Europe, Belgium), penicillin (200 μg/ml, 
BioWhittaker Europe, Belgium), and streptomycin (200 μg/ml, BioWhittaker Europe, 
Belgium) at 37 ºC under a CO2 (5%) atmosphere. After 24 hours of culture in the presence 
or the absence of 50 μg/ml of NanoMBGs, the attached RAW-264.7 cells were washed 
with phosphate buffered saline (PBS), harvested using cell scrapers and counted with a 
Neubauer hemocytometer for the analysis of cell proliferation. Then, cells were 
centrifuged at 310 g for 10 min, resuspended in fresh medium for the analysis of viability, 
cell size and complexity by flow cytometry as described below.  
2.7. Cell viability, size and complexity analysis by flow cytometry  
Cell viability was evaluated by exclusion of propidium iodide (PI; 0.005 % 
wt/vol in PBS, Sigma-Aldrich, St. Louis, MO, USA). PI was added to the cell 
suspensions in order to stain the DNA of dead cells. The fluorescence of PI was excited 
by a 15 mW laser tuning to 488 nm and the emitted fluorescence was measured with a 
530/30 band pass filter in a FACScalibur Becton Dickinson flow cytometer.  
Forward angle (FSC) and side angle (SSC) scatters were evaluated as indicative of 
cell size and complexity, respectively, using a FACScalibur Becton Dickinson flow 
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cytometer. The conditions for the data acquisition and analysis were established with the 
CellQuest Program of Becton Dickinson. 
2.8. Polarization of RAW-264.7 macrophages towards pro-inflammatory M1 and 
reparative M2 phenotypes. Flow cytometry and confocal microscopy studies 
To study the effect of NanoMBGs on macrophage polarization towards pro-
inflammatory M1 and reparative M2 phenotypes, RAW-264.7 macrophages were cultured 
with 50 μg/ml of these nanospheres for 24 h in the presence of either E. coli 
lipopolysaccharide (LPS, 250 ng/ml, Sigma-Aldrich Corporation, St. Louis, MO, USA) or 
interleukin 4 (IL-4, 20 ng/ml, Sigma-Aldrich Corporation, St. Louis, MO, USA) as pro-
inflammatory and reparative stimuli, respectively [32]. Controls without nanospheres and 
in the absence of stimuli were carried out in parallel. The expression of either CD80 as M1 
marker [33] or CD206 as M2 marker [32] was quantified by flow cytometry after treatment 
with specific antibodies. With this objective, after detachment and centrifugation, cells 
were incubated in 45 µl of staining buffer (PBS, 2.5% FBS Gibco, BRL and 0.1% sodium 
azide, Sigma-Aldrich Corporation, St. Louis, MO, USA) with 5 µl of normal mouse serum 
inactivated for 15 min at 4 ºC in order to block the Fc receptors on the macrophage plasma 
membrane, before adding the primary antibody, and to prevent non-specific binding. Then, 
to quantify the CD80 and CD206 expression by flow cytometry, cells were incubated with 
either phycoerythrin (PE) conjugated anti-mouse CD80 antibody (2.5 µg/ml, BioLegend, 
San Diego, California) or fluorescein isothiocyanate (FITC) conjugated anti-mouse CD206 
(2.5 µg/ml, BioLegend, San Diego, California) for 30 min in the dark. Labelled cells were 
analyzed using a FACSCalibur ﬂow cytometer. PE fluorescence was excited at 488 nm and 
measured at 585/42 nm. FITC fluorescence was excited at 488 nm and measured with a 
530/30 band pass filter. For confocal microscopy studies, macrophages cultured on glass 
coverslips were fixed with 3.7% paraformaldehyde (Sigma-Aldrich Corporation, St. Louis, 
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MO, USA) in PBS for 10 min, washed with PBS and permeabilized with 0.1% Triton X-
100 (Sigma-Aldrich Corporation, St. Louis, MO, USA) for 3 min. The samples were then 
washed with PBS and preincubated with PBS containing 1% BSA (Sigma-Aldrich 
Corporation, St. Louis, MO, USA) for 30 min to prevent non-specific binding. Samples 
were incubated in 1 ml of staining buffer with either phycoerythrin (PE) conjugated anti-
mouse CD80 antibody (2.5 µg/ml, BioLegend, San Diego, California) or fluorescein 
isothiocyanate (FITC) conjugated anti-mouse CD206 (2.5 µg/ml, BioLegend, San Diego, 
California) for 30 min at 4ºC in the dark. Samples were then washed with PBS and the cell 
nuclei were stained with 3 M DAPI (4′-6-diamidino-2′-phenylindole, Molecular Probes) 
for 5 min. Samples were examined using a Leica SP2 Confocal Laser Scanning 
Microscope. PE fluorescence was excited at 488 nm and measured at 575-675 nm. FITC 
fluorescence was excited at 488 nm and measured at 491-586 nm. DAPI fluorescence was 
excited at 405 nm and measured at 420–480 nm. 
2.9. Osteoclast differentiation from murine RAW 264.7 macrophages. Confocal 
microscopy studies 
Murine RAW-264.7 macrophages (2 x 10
4
 cells/ml) were seeded on glass 
coverslips and cultured in the presence of 50 μg/ml of NanoMBGs in Dulbecco's 
Modified Eagle Medium (DMEM), supplemented with 10% fetal bovine serum (FBS, 
Gibco, BRL), 1 mM L-glutamine (BioWhittaker Europe, Belgium), penicillin (200 
μg/ml, BioWhittaker Europe, Belgium), and streptomycin (200 μg/ml, BioWhittaker 
Europe, Belgium). To stimulate osteoclast differentiation, 40 ng/ml of mouse RANK 
Ligand recombinant protein (TRANCE/RANKL, carrier-free, BioLegend, San Diego) 
and 25 ng/ml recombinant human macrophage-colony stimulating factor (M-CSF, 
Milipore, Temecula) were added to the culture medium. It has been demonstrated that 
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M-CSF modulates multiple steps of human osteoclastogenesis and osteoclast-resorbing 
activity, but is not required for osteoclast survival [34]. Osteoclast precursors recognize 
RANKL through cell-to-cell interactions with osteoblasts and differentiate into 
osteoclasts in the presence of M-CSF. RANKL also stimulates the survival and bone-
resorbing activity of osteoclasts [35]. In our experimental conditions, we have 
previously shown that M-CSF and RANKL induce the differentiation from RAW-264.7 
macrophages into osteoclasts by stimulating their fusion as precursor cells and their 
osteoclast-resorbing activity [9,10]. Cells were cultured under a 5% CO2 atmosphere 
and at 37ºC for 7 days. Controls in the absence of nanospheres were carried out in 
parallel. For confocal microscopy studies, cells were washed with PBS, fixed with 3.7% 
paraformaldehyde in PBS for 10 min, permeabilizated with 0.1% Triton X-100 for 3 
min and preincubated with PBS containing 1% BSA for 30 min. Then, cells were 
incubated with rhodamine phalloidin (1:40, v/v Molecular Probes) for 20 min to stain F-
actin filaments. Samples were then washed with PBS and cell nuclei were stained with 3 
µM DAPI (4′-6-diamidino-2′-phenylindole; Molecular Probes) for 5 min. After 
mounting with Prolong Gold reagent (Thermo Fisher Scientific), cells were examined 
using a Leica SP2 Confocal Laser Scanning Microscope. Rhodamine fluorescence was 
excited at 540 nm and measured at 565 nm. DAPI fluorescence was excited at 405 nm 
and measured at 420–480 nm.  
2.10. Osteoclast resorption activity. Scanning electron microscopy studies 
To evaluate the resorption activity of osteoclasts, RAW-264.7 macrophages 
were seeded on the surface of nanocrystalline hydroxyapatite (nano-HA) disks and 
differentiate into osteoclasts in the presence of 50 μg/ml of NanoMBGs as it is 
described above. Nano-HA disks were prepared by controlled precipitation of calcium 
and phosphate salts and subsequently heated at temperatures below the sintering point, 
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as previously described by our research group [9]. Controls in the absence of 
nanospheres were carried out in parallel. After 7 days of differentiation, cells were 
detached using cell scrapers and disks were dehydrated, coated with gold-palladium and 
examined with a JEOL JSM-6400 scanning electron microscope in order to observe the 
geometry of resorption cavities produced by osteoclasts on the surface of nano-HA 
disks. 
2.11. Osteoblast/osteoclast coculture 
RAW-264.7 cells (American Type Culture Collection, ATCC) were seeded in 6 
well culture plates (Corning, USA), at a density of 2 x 10
4 
cells/ml, in 2.3 ml of 
Dulbecco's Modified Eagle Medium (DMEM) supplemented with 10% fetal bovine 
serum (FBS, Gibco, BRL), 1 mM L-glutamine (BioWhittaker Europe, Belgium), 
penicillin (200 μg/ml, BioWhittaker Europe, Belgium), and streptomycin (200 μg/ml, 
BioWhittaker Europe, Belgium). In order to stimulate osteoclast-like cell 
differentiation, 40 ng/ml of mouse RANK Ligand recombinant protein 
(TRANCE/RANKL, carrier-free, BioLegend, San Diego) and 25 ng/ml recombinant 
human macrophage-colony stimulating factor (M-CSF, Millipore, Temecula) were 
added to the culture medium. Simultaneously, Saos-2 osteoblasts were seeded at a 
density of 2 × 10
4
 cells/ml in transwell inserts (0.4 μm pore size, Corning, USA) in 1.3 
ml of the same culture medium and placed into the 6 well culture plates containing 
seeded RAW-264.7 cells (Scheme 1). This cocultures were carried out in the presence 
or the absence of 50 μg/ml of NanoMBGs without or with ipriflavone (NanoMBG-IPs) 
for 7 days at 37 ºC under a CO2 (5%) atmosphere. Separately, RAW-264.7 macrophages 
and Saos-2 osteoblasts were cultured alone in wells and transwell inserts, respectively 
as controls, to compare the results obtained with NanoMBGs and NanoMBG-IPs on 
these two cell types in coculture and separately without cell communication. For this 
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reason we maintained RANKL at the same dose for monoculture and coculture. After 
co-culturing, osteoblasts and osteoclast were washed with phosphate buffered saline 
(PBS), harvested using 0.25% trypsin-EDTA solution and cell scrapers respectively, 
and counted with a Neubauer hemocytometer for the analysis of cell number. Then, 
cells were centrifuged at 310 g for 10 min and resuspended in PBS for the analysis of 
cell cycle and viability by flow cytometry as described above. For confocal microscopy 
studies of cocultured osteoblasts and osteoclasts, Saos-2 osteoblasts and RAW-264.7 
cells were seeded on glass coverslips into transwell inserts and wells respectively, and 
cocultured as described above. After 7 days of coculture, cells were washed with PBS, 
fixed with 3.7% paraformaldehyde in PBS for 10 min, permeabilizated with 0.1% 
Triton X-100 for 3 min and preincubated with PBS containing 1% BSA for 30 min. 
Then, cells were incubated with rhodamine phalloidin (1:40, v/v Molecular Probes) for 
20 min to stain F-actin filaments. Samples were then washed with PBS and cell nuclei 
were stained with 3 µM DAPI (4′-6-diamidino-2′-phenylindole; Molecular Probes) for 5 
min. After mounting with Prolong Gold reagent (Thermo Fisher Scientific), cells were 
examined using a Leica SP2 Confocal Laser Scanning Microscope. Rhodamine 
fluorescence was excited at 540 nm and measured at 565 nm. DAPI fluorescence was 
excited at 405 nm and measured at 420–480 nm.  
To evaluate the resorption activity of osteoclasts in coculture, RAW-264.7 
macrophages were seeded on the surface of nano-HA disks into 6 well culture plates 
with differentiation medium (with RANKL and M-CSF) and cocultured with Saos-2 
osteoblasts previously seeded in the same well around nano-HA disks (Scheme 2). 
2.12. Incorporation of FITC-NanoMBGs by osteoblasts and osteoclasts 
The incorporation of FITC-NanoMBGs by osteoblasts and osteoclasts was 
quantified by flow cytometry after 3 days and 7 days of monoculture and coculture of these 
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cells with 50 μg/ml of FITC-NanoMBGs under the conditions described above. 
Osteoblasts and osteoclast were washed with phosphate buffered saline (PBS), harvested 
using 0.25% trypsin-EDTA solution and cell scrapers respectively, centrifuged at 310 g for 
10 min and resuspended in PBS for the analysis of FITC-NanoMBG incorporation by flow 
cytometry. FITC fluorescence was excited by a 15 mW laser tuning to 488 nm and 
measured with a 530/30 band pass filter in a FACScalibur Becton Dickinson Flow 
Cytometer. For confocal microscopy studies, cells were seeded on glass coverslips and 
cultured under the conditions described above. After 7 days of culture, cells were washed 
with PBS, fixed with 3.7% paraformaldehyde in PBS for 10 min, permeabilizated with 
0.1% Triton X-100 for 3 min and preincubated with PBS containing 1% BSA for 30 min. 
Then, cells were incubated with rhodamine phalloidin (1:40, v/v Molecular Probes) for 20 
min to stain F-actin filaments. Samples were then washed with PBS and cell nuclei were 
stained with 3 µM DAPI (4′-6-diamidino-2′-phenylindole; Molecular Probes) for 5 min. 
After mounting with Prolong Gold reagent (Thermo Fisher Scientific), cells were 
examined using a Leica SP2 Confocal Laser Scanning Microscope. Rhodamine 
fluorescence was excited at 540 nm and measured at 565 nm. FITC fluorescence was 
excited at 488 nm and measured at 491-586 nm. DAPI fluorescence was excited at 405 nm 
and measured at 420–480 nm. 
2.13. Statistics 
Data are expressed as means + standard deviations of a representative of three 
repetitive experiments carried out in triplicate. Statistical analysis was performed by 
using the Statistical Package for the Social Sciences (SPSS) version 22 software. 
Statistical comparisons were made by analysis of variance (ANOVA). Scheffé test was 
used for post hoc evaluations of differences among groups. In all statistical evaluations, 
p < 0.05 was considered as statistically significant. 
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3. Results and discussion 
3.1. Characterization of NanoMBGs and ipriflavone release test 
NanoMBGs were morphologically characterized by SEM and TEM. SEM 
micrographs (Figure 1 a) show that the NanoMBG material consists on monodisperse 
spherical nanoparticles of around 250 nm in diameter, although some nanoparticles have 
certain degree of polyhedral morphology. This fact would be a consequence of the use 
of CTAB as secondary template, as this surfactant is placed at the external location of 
the particles and often leads to hexagonal polyhedral morphologies [36]. TEM images 
show that NanoMBGs exhibit a hollow core-shell structure due to the double-template 
method used in this work (Figure 1 b). Higher magnification (Figure 1 c) reveals that 
the shell is organized into a radial mesoporous structure from the hollow core towards 
the external surface.  
Nitrogen adsorption/desorption isotherms (Figure 1 d) agree with this dual 
mesoporous structure. The adsorption curve corresponds to a type IV isotherm 
characteristic of mesoporous materials and the pore size is a monodispersed distribution 
centered at 2.3 nm, which would correspond to the mesopores of the outer shell. The 
size of the hollow core (about 200 nm) is too large to be measured by nitrogen 
adsorption and the pore size distribution could not be obtained. However, the H2 type 
hysteresis loop obtained with the desorption isotherm reveals a second kind of porosity 
with ink bottle morphology, which would indicate that the smaller pores of the shell are 
connected to the larger central pore of NanoMBGs.  
Ipriflavone (IP) was loaded into NanoMBGs obtaining values of 13% in weight 
determined by thermogravimetric analysis. The chemical compositions of both 
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NanoMBG and NanoMBG-IP nanospheres were determined by EDX spectroscopy 
during TEM observations and are also shown in Table 1. Despite of the incorporation of 
a phosphorous precursor as TEP during the synthesis, this element could not be detected 
by EDX, whereas silicon and calcium contents are very similar respect to the theoretical 
values. However, we decided to maintain the addition of TEP as we could observe that 
the presence of this reactive increased the content of Ca in NanoMBGs. In the absence 
of TEP, the calcium content in our nanoparticles could not overcome the 12 % value. 
Interestingly, NanoMBG-IPs keep the calcium content after the drug loading, which is a 
condition required for maintaining the bioactive behavior of mesoporous bioactive 
glasses [37,38]. This is possible due to the non-polar character of acetone used for the 
IP loading, which would avoid the calcium release commonly occurred when MBGs are 
soaked in aqueous mediums. 
Finally, the textural parameters obtained by N2 adsorption are shown in Table 1 
and evidence that the high surface area and porosity NanoMBGs are dramatically 
decreased after IP incorporation.  
Figure 2 a shows the FTIR spectra of NanoMBGs before and after loaded with 
IP (NanoMBG-IP), evidencing the incorporation of the drug with the appearance of the 
absorption bands corresponding to IP chemical groups. The drug delivery test (Figure 2 
b) shows a fast release of the 18% of the IP during the first 10 hours, followed by a 
slower release of an additional 6 % of drug before reaching an asymptotic behavior. The 
test was followed for 7 days without observing further IP release to the medium. Since 
the release test was carried out in isopropanol:water media, these results cannot be 
extrapolated to physiological conditions, where IP is almost insoluble Therefore, it 
should be considered just as a proof of the capability of nanoMBG for loading and 
release IP in a medium of low polarity. It must be pointed that, even using a release 
  
18 
 
media that facilitates IP release, most of IP is still retained within the core of NanoMBG 
nanospheres after 7 days, as could be confirmed by FTIR spectroscopy carried out on 
the particles collected after the drug release test (see Figure 2 a, NanoMBG-IP, 7 days). 
This behavior indicates that NanoMBG-IPs release a minor fraction of their payload by 
diffusion through the radial porosity of the shell, whereas most of the drug would be 
retained within the hollow core. In this sense, the total release of IP would be 
conditioned to nanoparticles degradation, thus ensuring the local long-term 
pharmacological treatment beyond the initial fast IP release. The degradation of MBGs 
has been widely studied and is initialized by an intense ionic exchange with the 
surrounding fluids [37,38]. In fact, this ionic exchange is the basis for their bone 
regenerative properties. It can be described as a sequence of reactions involving: 
a) Ca2+ by H+ ionic exchange between the material and the surrounding media. 
b) Release of soluble SiO2 oligomers from the material to the surrounding fluid. 
c) In the case of solutions with high calcium and phosphorous content (like the 
human plasma or cell culture media), a calcium phosphate phase very similar to 
the mineral component of the bone nucleates on the materials surface, thus 
ensuring the osteointegration of the MBGs with the hosting bone tissue.  
3.2. Effects of NanoMBGs on human Saos-2 osteoblasts 
Figure 3 shows the effects of NanoMBGs on proliferation (a), cell cycle profile 
(b) and cell cycle phases (c) of human Saos-2 osteoblasts cultured in the absence (white) 
or in the presence (grey) of 50 μg/ml of nanospheres for 24 hours. Saos-2 cells is an 
osteosarcoma cell line commonly used for in vitro evaluation of biomaterials designed 
for bone tissue due to its osteoblastic properties as production of mineralized matrix, 
high alkaline phosphatase levels, PTH receptors and osteonectin presence [39]. The 
analysis of the cell cycle by flow cytometry allows us to detect the percentage of cells in 
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the progressive stages: G0/G1 phase (Quiescence/Gap1), S phase (Synthesis) and finally 
G2/M phase (Gap2 and Mitosis). This analysis also indicates the percentage of apoptotic 
cells with fragmented DNA corresponding to the SubG1 fraction.  
The treatment with these nanospheres produced a significant S phase increase (p 
< 0.005) and a significant G2/M phase decrease (p < 0.05) after 24 h of treatment 
(Figure 3 c) that could be related to the observed, but no significant decrease detected in 
osteoblast number (proliferation, Figure 3 a) and G0/G1 phase (Figure 3 c). On the other 
hand, although this nanomaterial induced a significant increase of SubG1 fraction 
(p<0.005, Figure 3 c), very low levels of apoptosis were detected either in the absence 
or in the presence of these nanospheres. 
3.3. Effects of NanoMBGs on RAW-264.7 macrophages 
In order to know the effects of NanoMBG nanospheres on proliferation, 
viability, cell size and complexity of RAW-264.7 macrophages, these cells were 
cultured in the absence or in the presence of 50 μg/ml of nanospheres for 24 hours. 
Figure 4 shows that these nanoparticles did not induced significant alterations on cell 
proliferation, cell size and viability. However, a significant increase (p < 0.005) of cell 
complexity evaluated through the side angle scatter (SSC) was detected after the 
treatment with this nanomaterial. SSC is a special parameter of flow cytometry which 
can reflect the physical properties of a cell examined by the flow cytometer. It is a part 
of deflected laser light by the cell. The extent to which light scatters depends on the 
physical properties of a cell as its size and internal complexity. Factors that affect light 
scattering are the plasma membrane, cytoplasm, nucleus, mitochondria, pinocytic 
vesicles, lysosomes, and any granular material inside the cell. Cell shape and surface 
topography also contribute to the total light scattering [40,41]. Thus, the changes 
observed on SSC in Figure 4 could be due to the nanospheres uptake by macrophages. 
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The expression of either CD80 as M1 marker [33] or CD206 as M2 marker [32] 
after treatment with PE conjugated anti-mouse CD80 antibody or FITC conjugated anti-
mouse CD206 antibody is shown in Figures 5 a, b, c, d, f and g and observed by 
confocal microscopy (Figures 5 e and h).  
As it can be observed in Figures 5 a and b,  the treatment with NanoMBGs in 
basal conditions (without stimulus) did not induce significant changes of M1 percentage 
and CD80 expression (M1 fluorescence intensity) but produced a significant increase of 
M2 percentage (p<0.05) accompanied by a significant decrease of CD206 fluorescence 
intensity (M2, p<0.01). This M2 fluorescence intensity corresponds to the mean 
fluorescence of the CD206
+
 population (M2). This M2 population presented a slight but 
significant increase of cell number after treatment with nanospheres but, probably due 
to this fact, the mean fluorescence of this population shifts to a lower value. When 
macrophages were treated with LPS as inflammatory stimulus (Figures 5 c and d), these 
nanospheres did not modify M1 percentage but increased CD80 fluorescence intensity 
(M1, p<0.005), evidencing a higher response capability against the LPS stimulus in the 
presence of material. On the other hand, when macrophages were treated with IL-4 as 
reparative stimulus (Figures 5 f and g), NanoMBGs induced significant increases of 
both M2 percentage and CD206 expression (M2 fluorescence intensity, p<0.005). These 
results evidence that NanoMBGs did not induce the macrophage polarization towards 
the M1 pro-inflammatory phenotype in basal conditions, promoting  the control of the 
M1/M2 balance with a slight shift towards M2 reparative phenotype and increasing the 
response capability against both stimuli LPS and IL-4. All these data ensure an 
appropriate immune response to these nanospheres. On the other hand, the macrophage 
phenotype polarization has been related to changes in cell shape [42] that were also 
observed in the present study when macrophages were stimulated with either LPS or IL-
4 as pro-inflammatory and reparative stimulus, respectively. Thus, macrophages 
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polarized towards the M1 (CD80
+
) phenotype with LPS showed more spherical shape 
(Figure 5 e) than cells polarized towards the M2 (CD206
+
) phenotype with IL-4 
showing an elongated shape (Figure 5 h), in agreement with other authors [42] and 
previous studies [43]. 
3.4. Incorporation FITC-NanoMBGs by osteoclasts and osteoblasts in monoculture and 
in coculture with each other. 
Figure 6 shows the incorporation of NanoMBGs labelled with FITC by 
osteoclasts and osteoblasts in monoculture (OC and OB) and in coculture (OC-co and 
OB-co) with each other. The percentage of cells with intracellular FITC-NanoMBGs 
and the fluorescence intensity of these cells were quantified by flow cytometry after 3 
days (Figure 6 a) and 7 days (Figure 6 b). Confocal microscopy studies were carried out 
to observe these nanospheres incorporated by osteoclasts (Figure 6 d) and osteoblasts 
(Figure 6 f) in coculture after 7 days. Control cocultures of osteoclasts (Figure 6 c) with 
osteoblasts (Figure 6 e) in the absence of nanospheres were carried out in parallel. 
As it can be observed in Figure 6 b, the percentage of cells with FITC-
NanoMBGs and the fluorescence intensity of these cells were significantly higher in 
monocultured and cocultured osteoblasts than in monocultured and cocultured 
osteoclasts after 7 days of treatment (p<0.005). Confocal microscopy studies evidenced 
that after FITC-NanoMBG incorporation, osteoclasts and osteoblasts maintained their 
characteristic morphology in both monocultures (data not shown) and cocultures 
(Figures 6 d and f, respectively) in comparison with control monocultures (data not 
shown) and cocultures (Figures 6 c and e, respectively). These results evidenced that 
FITC-NanoMBG incorporation did not induced alterations in osteoclast and osteoblast 
morphology, allowing the osteoclastogenesis process that was confirmed by the 
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observation of multinucleated cells with the F-actin ring (Figure 6 d), that allows 
creation of the "sealing zone", critical for bone resorption [14,15]. 
Figure 7 shows the cell number (7 a) and cell viability (7 b) of osteoclasts (OC) 
and osteoblasts (OB) in coculture with each other after 7 days of treatment with 50 
μg/ml of either NanoMBG (OC-co and OB-co) or NanoMBG-IP (Oc-co/IP and OB-
co/IP) nanospheres. As it can be observed, the presence of ipriflavone induced a 
significant decrease of osteoclast number (p<0.005) without affecting the viability of 
this cell type. On the other hand, ipriflavone did not induce changes on osteoblast 
proliferation and viability. The cell morphology of osteoclasts and osteoblasts in 
coculture in the presence of nanospheres without IP (7 c and 7 e, respectively) or with 
IP (7 d and 7 f, respectively) did not show alterations. 
Figure 8 shows the resorption cavities left by osteoclasts on nanocrystalline 
hydroxyapatite disks after 7 days of differentiation in monoculture (a), in coculture with 
osteoblasts (b), in coculture with osteoblasts in the presence of 50 μg/ml of NanoMBGs 
(c and d) and in coculture with osteoblasts in the presence of 50 μg/ml of NanoMBG-
IPs (e and f). As it can be observed, the dimensions of these cavities significantly 
decreased when osteoclasts are cocultured with osteoblasts (Figure 8 b) in comparison 
with the cavities left by osteoclasts in monoculture (Figure 8 a), evidencing that the 
presence of osteoblasts modulates the resorption activity of osteoclasts. These results 
could be due to the osteoblast production of osteoprotegerin (OPG), a soluble receptor 
that acts as a decoy receptor for RANKL and negatively regulates osteoclast 
differentiation [11]. The cavities left by osteoclasts in coculture and in the presence of 
NanoMBGs without ipriflavone (IP) (Figures 8 c and d) were similar to those obtained 
in the absence of spheres (Figure 8 b). However, in the presence of IP-loaded 
NanoMBGs, osteoclasts in coculture exhibited a lower resorptive activity and 
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superficial erosion marks were observed (Figures 8 e and f), probably due to the IP 
action in agreement with the mechanisms of this agent [44]. Different authors have 
demonstrated that the bone-resorbing activity of osteoclasts is regulated by Ca
2+
 levels 
and that high concentrations of this cation produce osteoclast retraction and dissipation 
of sealing zone, decreasing the bone resorption process [45,46]. Concerning IP 
mechanism, it has been described that IP inhibits the fusion of osteoclast precursor cells, 
bone resorption and tartrate-resistant acid phosphatase activity. These effects are 
mediated by specific IP receptors that induce a rapid increase in intracellular [Ca
2+
] 
followed by a sustained elevation of this cation in osteoclasts and their precursor cells 
[44]. It must be highlighted that only a minor fraction of IP is released after 7 days from 
NanoMBG-IPs when soaked in isopropanol: water solution, in which IP is highly 
soluble. In cell culture media, the supposedly smaller amount of IP released seems to be 
enough to decrease the resorptive activity of osteoclasts. We envision that this behavior 
could be beneficial for the local delivery treatment of osteoporotic bone. Osteoporosis 
requires prolonged periods of drug administration. In the case of IP, the bioactive 
dosage strongly varies depending on the administration way. For instance, IP 
biodisponibility in plasma after oral administration is only 20% and around 120 mg per 
day of ipriflavone is required in plasma. The loading rate of IP in NanoMBGs is 13% 
and the in vitro release test suggests that only a minor fraction of the payload by 
diffusion through the radial pores of the shell. However, in contact with bone cells, this 
payload seems to be enough to initially decrease the resorptive activity of osteoclasts.  
 
 
4. Conclusions 
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Mesoporous bioactive nanospheres in the system SiO
2
-CaO (NanoMBGs) have 
been prepared via dual template method. NanoMBGs exhibit a hollow core and a radial 
mesoporous arrangement at the shell. The porous structure of these nanospheres 
allowed the loading of ipriflavone obtaining NanoMBG-IPs. However, ipriflavone is a 
highly insoluble compound in aqueous environment like culture media or human 
plasma. Even in low-polar conditions, where IP is highly soluble, most of the drug 
remains retained  within the nanoparticles core. This fact would suggest that, under less 
favorable hydric physiological conditions, IP would be kept for longer periods, and it 
would enable the local long term pharmacological treatment. 
NanoMBGs did not induce the macrophage polarization towards the M1 pro-
inflammatory phenotype in basal conditions, promoting  the control of the M1/M2 
balance with a slight shift towards M2 reparative phenotype, increasing the response 
capability against stimuli (LPS and IL-4) and ensuring an appropriate immune response. 
The intracellular incorporation of FITC-NanoMBG after 7 days, detected in 
monocultures and cocultures of osteoblasts and osteoclasts, was significantly higher in 
osteoblasts. NanoMBG-IPs induced a significant decrease of osteoclast cell number and 
resorption activity in coculture with osteoblasts without affecting osteoblast 
proliferation and viability. All these data ensure an appropriate immune response to 
these nanospheres and the potential application of NanoMBG-IPs as local drug delivery 
system in osteoporotic patients. Further studies will be performed with in vivo models in 
order to determine the advantages of these NanoMBG-IPs to other anti-osteoporotic 
treatments and these results will be included in a future manuscript. 
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SCHEMES 
 
 
Scheme 1. Cocultures of human Saos-2 osteoblasts and osteoclast-like cells 
differentiated from RAW-264.7 macrophages in the presence of RANKL and M-CSF 
were carried to evaluate the incorporation and effects of 50 μg/ml of NanoMBG 
nanospheres with or without ipriflavone. 
 
 
 
 
 
 
 
 
Scheme 2. Cocultures of human Saos-2 osteoblasts (OB) and osteoclast-like cells 
differentiated from RAW-264.7 macrophages in the presence of RANKL and M-CSF 
on nanocrystalline hydroxyapatite disks were carried to evaluate the effects of 50 μg/ml 
of NanoMBG nanospheres with or without ipriflavone on the resorption activity of 
osteoclasts. 
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TABLES 
 
 
 
 
Table 1. Chemical composition and textural properties of NanoMBG nanospheres 
before and after loading with ipriflavone. Values in brackets correspond to the 
theoretical chemical composition. 
Sample Si 
(% atom) 
Ca 
(% atom) 
P 
(% atom) 
Surface 
area 
(m
2
·g
-1
) 
Porosity 
(cm
3
g
-1
) 
Pore size 
(nm) 
NanoMBG 81.44 
(79.4) 
 
18.56 
(18.1) 
- 
(2.5) 
543.6 0.435 2.2 
NanoMBG-IP 83.36 16.63 - 14.2 0.057 NA 
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FIGURES 
 
 
 
 
 
 
Figure 1. Scanning electron micrograph of NanoMBG nanospheres (a), high resolution 
transmission electron microscopy image of NanoMBG nanospheres (b and c), 
adsorption-desorption isotherms and pore size distribution (d).   
  
  
34 
 
 
 
 
 
 
 
 
Figure 2. FTIR spectra of NanoMBG and NanoMBG-IP nanospheres before and after 
seven days of drug release test. * points absorption bands corresponding to the different 
functional groups of ipriflavone (a). Ipriflavone released as a function of soaking time 
(b). 
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Figure 3. Effects of NanoMBG nanospheres on proliferation and cell cycle of human 
Saos-2 osteoblasts: a) proliferation, b) cell cycle profiles and c) cell cycle phases of 
cells cultured in the absence (white) or in the presence (grey) of 50 μg/ml of 
nanospheres for 24 hours. Statistical significance: *p < 0.05; *** p < 0.005.  
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Figure 4. Effects of NanoMBG nanospheres on proliferation, cell viability, size and 
complexity of RAW-264.7 macrophages cultured in the absence (white) or in the 
presence (grey) of 50 μg/ml of nanospheres for 24 hours. Statistical significance: *** p 
< 0.005.  
  
  
37 
 
 
Figure 5. Effects of NanoMBG nanospheres on pro-inflammatory M1 and reparative 
M2 phenotypes of RAW-264.7 macrophages after 24 hours of treatment without 
stimulus (a and b) or with E. coli lipopolysaccharide (LPS) (c, d and e)as inflammatory 
stimulus or with interleukin 4 (IL-4) (f, g and h) as reparative stimulus. Cells were 
cultured in the absence (white) or in the presence (grey) of 50 μg/ml of nanospheres for 
24 hours. Statistical significance: * p < 0.05, ** p < 0.01, *** p < 0.005. Confocal 
images show the CD80 (e) and CD206 (h) expression of M1 and M2 RAW-264.7 
macrophages after treatment with LPS or IL-4 respectively, and in the presence of 50 
μg/ml of nanospheres for 24 hours. CD80 (red) was detected with PE conjugated anti-
mouse CD80 antibody, CD206 (green) was detected with FITC conjugated anti-mouse 
CD206 antibody, nuclei were stained with DAPI (blue). 
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Figure 6. Incorporation of NanoMBG nanospheres labelled with FITC by osteoclasts 
and osteoblasts in monoculture (OC, OB) and in coculture with each other (OC-co, OB-
co). Figures 6a and 6b show the flow cytometric analysis of intracellular incorporation 
of FITC-NanoMBG nanospheres (percentage of green fluorescent cells) and the 
fluorescence intensity (green line, arbitrary units) after 3 days (a) and 7 days (b). 
Confocal microscopy images of FITC-NanoMBG nanospheres incorporated by 
osteoclasts (d) and osteoblasts (f) in coculture with each other after 7 days. In the 
absence of nanospheres, control cocultures of osteoclasts (c) with osteoblasts (e) were 
carried out in parallel. 
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Figure 7. Cell number (a) and cell viability (b) of osteoclasts (OC) and osteoblasts 
(OB) in coculture with each other after 7 days with 50 μg/ml of either NanoMBG (OC-
co and OB-co) or ipriflavone (IP)-loaded NanoMBG (Oc-co/IP and OB-co/IP) 
nanospheres. Cell morphology of OC-co (c), OC-co/IP (d), OB-co (e) and OB-co/IP (f).  
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Figure 8. Scanning electron microscopy images of the resorption cavities left by 
osteoclasts after 7 days in monoculture (a), in coculture with osteoblasts (b), in 
coculture with osteoblasts in the presence of 50 μg/ml of NanoMBG nanospheres (c and 
d) and in coculture with osteoblasts in the presence of 50 μg/ml of NanoMBG-IP 
nanospheres (e and f). 
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